FDA warned telehealth seller Vitals RX that its website falsely implies compounded semaglutide and tirzepatide are the approved drug Ozempic.
What happened
FDA reviewed the website vitalsrx.com in August 2025 and found it offering compounded semaglutide and tirzepatide products. The site used the line "Vitals RX - Semaglutide/Tirzepatide/Ozempic Weight Loss Clinic," even though the only semaglutide and tirzepatide products it sells are compounded and not FDA-approved. FDA says that wording falsely suggests the compounded products are the same as an FDA-approved drug, which makes them misbranded (misbranded means the labeling is false or misleading).
What FDA found
The website claim suggests the compounded drugs are the same as FDA-approved Ozempic, when they are not, so the labeling is false or misleading.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising or promoting a compounded drug in a false or misleading way makes it misbranded.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Sending these misbranded drugs into interstate commerce is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]The compounded semaglutide and tirzepatide are 'new drugs' not generally recognized as safe and effective for their labeled uses.
FDCA section 201(p) [21 U.S.C. § 321(p)]
What FDA wants
FDA tells the company to take immediate action, including stopping use of the misleading Ozempic wording, and to send a written response to its Office of Compounding Quality and Compliance describing the corrective steps taken and how repeat violations will be prevented. If the company cannot fully address the matter in time, it must say why and give a date when it will.
Who should pay attention
- telehealth and online pharmacy sites selling compounded GLP-1 drugs
- compounding pharmacies that supply such websites
- marketing and compliance staff who review drug claims on websites
This is a summary. Read the original letter on fda.gov.